Thomas Kerbusch

2.4k total citations
47 papers, 1.9k citations indexed

About

Thomas Kerbusch is a scholar working on Pathology and Forensic Medicine, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, Thomas Kerbusch has authored 47 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 9 papers in Pediatrics, Perinatology and Child Health and 8 papers in Molecular Biology. Recurrent topics in Thomas Kerbusch's work include Chemotherapy-induced organ toxicity mitigation (16 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Statistical Methods in Clinical Trials (7 papers). Thomas Kerbusch is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (16 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Statistical Methods in Clinical Trials (7 papers). Thomas Kerbusch collaborates with scholars based in Netherlands, United States and United Kingdom. Thomas Kerbusch's co-authors include Mats O. Karlsson, Radojka M. Savić, Daniël M. Jonker, Jos H. Beijnen, Alwin D. R. Huitema, Meindert Danhof, Sandra A. G. Visser, Zereunesay Desta, D. A. Flockhart and H.J. Keizer and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, British Journal of Cancer and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Thomas Kerbusch

46 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Kerbusch Netherlands	22	411	359	347	239	239	47	1.9k
Richard Peck United Kingdom	25	295 0.7×	176 0.5×	183 0.5×	132 0.6×	126 0.5×	64	1.5k
Christopher Banfield United States	30	328 0.8×	425 1.2×	515 1.5×	426 1.8×	158 0.7×	88	2.8k
Brian P. Smith United States	29	359 0.9×	141 0.4×	194 0.6×	213 0.9×	177 0.7×	100	2.8k
Thorsten Lehr Germany	30	470 1.1×	632 1.8×	528 1.5×	309 1.3×	109 0.5×	120	3.8k
Bart A. Ploeger Netherlands	26	630 1.5×	498 1.4×	364 1.0×	230 1.0×	53 0.2×	67	2.3k
Iñaki F. Trocóniz Spain	31	756 1.8×	298 0.8×	887 2.6×	423 1.8×	108 0.5×	187	3.6k
John H. Rodman United States	27	422 1.0×	226 0.6×	455 1.3×	253 1.1×	188 0.8×	66	2.4k
Nitin Mehrotra United States	22	360 0.9×	141 0.4×	395 1.1×	166 0.7×	71 0.3×	59	1.8k
Rashmi R. Shah United Kingdom	33	1.4k 3.3×	518 1.4×	608 1.8×	211 0.9×	118 0.5×	85	3.4k
Karin Jorga Switzerland	25	382 0.9×	325 0.9×	388 1.1×	136 0.6×	44 0.2×	48	2.0k

Countries citing papers authored by Thomas Kerbusch

Since Specialization

Citations

This map shows the geographic impact of Thomas Kerbusch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Kerbusch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Kerbusch more than expected).

Fields of papers citing papers by Thomas Kerbusch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Kerbusch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Kerbusch. The network helps show where Thomas Kerbusch may publish in the future.

Co-authorship network of co-authors of Thomas Kerbusch

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Kerbusch. A scholar is included among the top collaborators of Thomas Kerbusch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Kerbusch. Thomas Kerbusch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weber, Frank, et al.. (2024). The Newborn Infant Parasympathetic Evaluation Index for Assessment of Procedural Pain and Discomfort in Mechanically Ventilated Pediatric Intensive Care Patients: A Prospective, Exploratory, Observational Study. Pediatric Anesthesia. 35(3). 232–238.

Zandvliet, Anthe S., Eva Gil Berglund, Billy Amzal, et al.. (2020). Artificial Intelligence and Machine Learning Applied at the Point of Care. Frontiers in Pharmacology. 11. 759–759. 60 indexed citations

Kimball, Alexa B., Thomas Kerbusch, Andrew Blauvelt, et al.. (2019). Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. British Journal of Dermatology. 182(1). 180–189. 21 indexed citations

Post, Teun M., et al.. (2015). Prediction of nomegestrol acetate pharmacokinetics in healthy female adolescents and adults by whole-body physiology-based pharmacokinetic modelling and clinical validation. Contraception. 93(2). 133–138. 4 indexed citations

Post, Teun M., Stephan Schmidt, L. A. Peletier, et al.. (2013). Application of a mechanism-based disease systems model for osteoporosis to clinical data. Journal of Pharmacokinetics and Pharmacodynamics. 40(2). 143–156. 23 indexed citations

Kleijn, Huub Jan, et al.. (2011). Population pharmacokinetic–pharmacodynamic analysis for sugammadex‐mediated reversal of rocuronium‐induced neuromuscular blockade. British Journal of Clinical Pharmacology. 72(3). 415–433. 39 indexed citations

Post, Teun M., Serge C.L.M. Cremers, Thomas Kerbusch, & Meindert Danhof. (2010). Bone Physiology, Disease and Treatment. Clinical Pharmacokinetics. 49(2). 89–118. 36 indexed citations

Johnson, Trevor N., Thomas Kerbusch, Barry Jones, et al.. (2009). Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug–drug interactions: usingin vitrodata as an aid to assess study power. Pharmaceutical Statistics. 8(3). 186–202. 11 indexed citations

Savić, Radojka M., Daniël M. Jonker, Thomas Kerbusch, & Mats O. Karlsson. (2007). Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. Journal of Pharmacokinetics and Pharmacodynamics. 34(5). 711–726. 401 indexed citations

10.

Kerbusch, Thomas, Gerard Groenewegen, Ron A. A. Mathôt, et al.. (2004). Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. British Journal of Cancer. 90(12). 2268–2277. 4 indexed citations

11.

Kerbusch, Thomas, Peter A. Milligan, & Mats O. Karlsson. (2003). Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic–pharmacodynamic data. British Journal of Clinical Pharmacology. 57(2). 170–180. 25 indexed citations

12.

Kerbusch, Thomas, et al.. (2001). Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients. Cancer Chemotherapy and Pharmacology. 48(1). 53–61. 10 indexed citations

13.

Kerbusch, Thomas, et al.. (2001). Distribution of ifosfamide and metabolites between plasma and erythrocytes. Biopharmaceutics & Drug Disposition. 22(3). 99–108. 8 indexed citations

14.

Kerbusch, Thomas, et al.. (2001). Population Pharmacokinetics of Ifosfamide and its Dechloroethylated and Hydroxylated Metabolites in Children with Malignant Disease. Clinical Pharmacokinetics. 40(8). 615–625. 18 indexed citations

15.

Kerbusch, Thomas, Alwin D. R. Huitema, Jannemieke Ouwerkerk, et al.. (2000). Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. British Journal of Clinical Pharmacology. 49(6). 555–561. 39 indexed citations

16.

Kerbusch, Thomas, et al.. (2000). Determination of Ifosfamide, 2- and 3-Dechloroethyifosfamide Using Gas Chromatography With Nitrogen-Phosphorus or Mass Spectrometry Detection. Therapeutic Drug Monitoring. 22(5). 613–620. 16 indexed citations

17.

Desta, Zereunesay, Thomas Kerbusch, & D. A. Flockhart. (1999). Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clinical Pharmacology & Therapeutics. 65(1). 10–20. 92 indexed citations

18.

Desta, Zeruesenay, et al.. (1998). Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide. Journal of Pharmacology and Experimental Therapeutics. 285(2). 428–437. 62 indexed citations

19.

Kerbusch, Thomas, Alwin D. R. Huitema, J. J. Kettenes‐van den Bosch, et al.. (1998). High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes. Journal of Chromatography B Biomedical Sciences and Applications. 716(1-2). 275–284. 19 indexed citations

20.

Kerbusch, Thomas, Zeruesenay Desta, Nadia Soukhova, David Thacker, & David A. Flockhart. (1997). Sensitive assay for pimozide in human plasma using high-performance liquid chromatography with fluorescence detection: application to pharmacokinetic studies. Journal of Chromatography B Biomedical Sciences and Applications. 694(1). 163–168. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact